Clinical Evaluation of a Resorbable PLLA Implant for Regeneration of the Anterior Cruciate Ligament (ACL)
NCT ID: NCT01634711
Last Updated: 2021-11-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
15 participants
INTERVENTIONAL
2013-06-30
2019-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The proposed study is a prospective, consecutive, non-randomized, multicentre clinical trial conducted at up to five European sites, wherein 15 study subjects will undergo primary ACL reconstruction with the L-C Ligament. After screening procedures are completed, eligible study subjects who provide written informed consent will be enrolled in the study. Subjects will undergo preoperative clinical, MRI, and radiographic evaluations and undergo primary ACL reconstruction. Follow-up clinical evaluations will be performed post-op (range 1-8 weeks), 3 months (± 3 weeks), 6 months (± 3 weeks), 12 months (± 1 month), and 24 months (± 2 months) after surgery. Assessment of safety (i.e., assessment of adverse events and complications), pain, and clinical function as well as imaging will occur.
In accordance with a separate radiographic protocol, analysis and scoring of MRI images (pre-op, 1 and 2 years), radiographs (pre- and post- op), and a CT scan post-op and at 1-year will be undertaken by an independent radiologist who will be masked to the identities of the subjects and clinical investigators. Outcome measures for imaging include position of the bone tunnels and interference screws, indirect evidence of ligament tissue remodeling, and evidence of tunnel-widening. Evidence of OA will also be monitored. The Principal Investigator and Co-Investigators will ensure that complications observed on radiographs, MRI, and CT images are reported to their ethics committee and the sponsor.
The primary objective of this study is to evaluate the safety of the L-C Ligament in primary ACL reconstruction. Safety will be evaluated by the occurrence, frequency, and severity of intra- and post- operative complications; the primary end point is one year and follow-up wil be performed for a minimum of two years. Clinical function will be assessed with the IKDC-2000 Scale and functionality of the device at two years follow-up.
The secondary objectives of this study are to determine efficacy by objectively and subjectively measuring pain, function, and the results of image analyses of the L-C Ligament in primary ACL reconstruction. Objective measures include the Lachman test, the anterior drawer test, the KT-1000 Arthrometer, the pivot-shift test, and the single-leg hop test. Pre- and post- operative objective and subjective measures include the Tegner and Lysholm scales. Pre- and post- op radiographs, MRI images pre-op, and at 1 and 2 years, and post-op and 1-year CT scans will be analyzed for position of the bone tunnels and screws, indirect evidence of ligament tissue remodeling, and evidence of widening of the bone tunnels.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
The L-C Ligament
Soft Tissue Regeneration's L-C Ligament is an interventional device intended for ACL reconstruction surgery within 13 weeks of acute rupture of the ACL and no previous treatment. The L-C Ligament temporarily replaces the human anterior cruciate ligament (ACL) and provides a bioresorbable scaffold within and around which the native ACL will regenerate over time.
L-C Ligament
The L-C Ligament is a bioresorbable, three-dimensional (3-D) braided scaffold made from poly L-lactic acid (PLLA) fiber. One device is used to replace the ACL. The L-C Ligament is an interventional device. The L-C Ligament is comprised of three regions: (1) The femoral tunnel attachment site, (2) The ligament region (intra-articular zone), and (3) The tibial tunnel attachment site. For several months after surgery, the L-C Ligament replaces the function of the ACL. During this time, ligament tissue regenerates within and around the L-C Ligament, which is slowly absorbed and replaced by the ACL.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
L-C Ligament
The L-C Ligament is a bioresorbable, three-dimensional (3-D) braided scaffold made from poly L-lactic acid (PLLA) fiber. One device is used to replace the ACL. The L-C Ligament is an interventional device. The L-C Ligament is comprised of three regions: (1) The femoral tunnel attachment site, (2) The ligament region (intra-articular zone), and (3) The tibial tunnel attachment site. For several months after surgery, the L-C Ligament replaces the function of the ACL. During this time, ligament tissue regenerates within and around the L-C Ligament, which is slowly absorbed and replaced by the ACL.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Males and females.
3. If female, for the 24 months post-operative, actively practicing a contraception method, or surgically sterilised or postmenopausal.
4. Acute unilateral ACL tear, or partial or complete tear of the ACL that occurred within 18 weeks of injury, and requires reconstruction of the ACL.
5. Passive flexion ≥ 120° and passive extension on the target knee is the same as the contralateral knee.
6. Patients with all types of lateral and/or medial meniscal tears which are repairable.
7. Medial Collateral Ligament (MCL) grade 2 or less. Potential Subject is able to provide informed consent and must sign the EC-approved Informed Consent Form.
8. Must be physically and mentally willing and able to comply with post-operative rehabilitation and routinely scheduled clinical, radiographic and rehabilitation follow up visits through 24 months.
Exclusion Criteria
2. Chronic ACL injury; interventional surgery scheduled 18 weeks or more after ACL injury.
3. Professional athletes currently engaged in active sport
4. Prior fracture of the affected (target) leg
5. Previous or current ACL injury on contra-lateral leg.
6. Multi-ligament reconstruction.
7. Malalignment with varus thrust
8. Patient greater than 193 cm tall (6' 4").
9. The patient does not follow pre-operative rehabilitation.
10. Confirmed connective tissue disorder.
11. Signs of moderate to severe degenerative joint disease (Osteoarthritis)
12. Concomitant injuries to the knee or lower extremities requiring treatment, per surgeon's discretion.
13. Severe pain, swelling, or redness within 24 hours prior to surgery.
14. Complete or partial Post Cruciate Ligament (PCL) tear.
15. Any of the following: 1/3rd meniscal resection; complex double-bucket tear; partially repaired meniscal tears.
16. Patient requires treatment of articular cartilage on target leg
17. The patient is mentally compromised.
18. The patient has a neuromuscular disorder that would engender unacceptable risk of knee instability, prosthesis fixation failure, or complications in postoperative care.
19. The patient has a diagnosed systemic disease that would affect his/her safety or the study outcome.
20. The patient has an active or latent infection in or about the affected knee joint or an infection site distant from the knee that may spread to the knee hematogenously.
21. Pregnant based on a positive beta hCG serum or an in vitro diagnostic test result or breast-feeding.
22. The patient is obese with a BMI greater than or equal to 35.
23. The patient has a known allergy to PLLA.
24. The patient has a medical condition or comorbidity that would interfere with study participation.
18 Years
45 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Soft Tissue Regeneration, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Martini ziekenhuis
Groningen, , Netherlands
Isala Klinieken - locatie Weezenlanden
Zwolle, , Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
For additional info and business inquries, visit www.softtissueregeneration.com or contact Joe Reilly, CEO, at [email protected]
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LC 1033, Version 3.0
Identifier Type: -
Identifier Source: org_study_id